Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results

Rhea-AI Summary

Legend Biotech (NASDAQ: LEGN), a global cell therapy leader, has scheduled an investor conference call for Monday, August 11, 2025, at 8:00 am ET to discuss their second quarter 2025 financial results. The company's senior leadership will present the quarterly performance overview during the call.

Investors can access the live audio webcast through a provided weblink. Following the call, both the webcast replay and earnings release will be accessible on Legend Biotech's website in the Investor Relations section under Events and Presentations, approximately two hours after the call's conclusion.

News Market Reaction – LEGN

-4.27%

1 alert

-4.27% News Effect

On the day this news was published, LEGN declined 4.27%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOMERSET, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, August 11, 2025, to review second-quarter 2025 results.

During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter.

Investors and other interested parties may join the live audio webcast of the call via this weblink.

A replay of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech’s website under the Events and Presentations section approximately two hours after the call concludes.

ABOUT LEGEND BIOTECH

With over 2,600 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI^®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at www.legendbiotech.com, and follow us on X (formerly Twitter) and LinkedIn.

INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com

PRESS CONTACT:
Mary Ann Ondish
Tel: (914) 552-4625
media@legendbiotech.com

FAQ

When is Legend Biotech's Q2 2025 earnings call?

Legend Biotech's Q2 2025 earnings call is scheduled for Monday, August 11, 2025, at 8:00 am ET.

How can investors access Legend Biotech's Q2 2025 earnings call?

Investors can access the live audio webcast through a weblink provided by the company. The replay will be available on Legend Biotech's website under the Investor Relations section's Events and Presentations.

When will Legend Biotech's Q2 2025 earnings materials be available?

The earnings release and webcast replay will be available on Legend Biotech's Investor Relations website approximately two hours after the call concludes.

Who will present during Legend Biotech's Q2 2025 earnings call?

Senior leaders from Legend Biotech will provide an overview of the company's performance for the quarter.